Short Interest in Apollomics, Inc. (NASDAQ:APLM) Increases By 39,293.9%

Apollomics, Inc. (NASDAQ:APLM) was the target of a large growth in short interest during the month of October. As of October 31st, there was short interest totalling 1,300,000 shares, a growth of 39,293.9% from the October 15th total of 3,300 shares. Approximately 27.8% of the shares of the company are sold short. Based on an average daily volume of 1,660,000 shares, the days-to-cover ratio is currently 0.8 days.

Apollomics Price Performance

APLM opened at $0.82 on Friday. Apollomics has a fifty-two week low of $0.55 and a fifty-two week high of $49.00. The stock has a fifty day moving average of $2.58 and a 200-day moving average of $4.15.

Analyst Ratings Changes

Separately, HC Wainwright cut their price target on Apollomics from $18.00 to $17.00 and set a “buy” rating for the company in a report on Tuesday, October 3rd.

Institutional Investors Weigh In On Apollomics

A number of hedge funds and other institutional investors have recently modified their holdings of APLM. George Kaiser Family Foundation acquired a new stake in shares of Apollomics during the first quarter worth $16,238,000. Clear Street LLC acquired a new stake in shares of Apollomics during the first quarter worth $165,000. Geode Capital Management LLC acquired a new position in Apollomics in the first quarter valued at about $325,000. Exchange Traded Concepts LLC bought a new stake in Apollomics during the second quarter worth about $166,000. Finally, Levin Capital Strategies L.P. acquired a new stake in Apollomics during the second quarter worth about $62,000. Institutional investors and hedge funds own 1.62% of the company’s stock.

Apollomics Company Profile

Apollomics, Inc, a biotechnology company, engages in the discovery and development of oncology therapies to address unmet medical needs in California, Hangzhou, Shanghai, China, and Australia. It develops APL-101 (Vebreltinib), a potent, selective c-Met inhibitor for the treatment of non-small cell lung cancer and other advanced tumors; APL-102 is an oral active, small molecule multiple tyrosine kinase inhibitor for liver cancer, breast cancer, and esophageal cancer; and APL-122, a tumor inhibitor candidate to treat cancers within the brain.